Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457322 | 0.92 | FAAH (0.64) | FAAHTRPV1KDM2BKDM4ENPC1 | |
| SCHEMBL2456948 | 0.91 | FAAH (0.62) | FAAHTRPV1KDM2BKDM4ENPC1 | |
| SCHEMBL2458662 | 0.89 | FAAH (0.60) | FAAHTRPV1KDM2BKDM4ENPC1 | |
| SCHEMBL2459086 | 0.86 | FAAH (0.57) | FAAHTRPV1KDM2BKDM4ENPC1 | |
| SCHEMBL3936930 | 0.85 | FAAH (1.00) | FAAHTRPV1KDM2BKDM4ENPC1 | |
| SCHEMBL2458879 | 0.85 | FAAH (0.56) | FAAHTRPV1KDM4ENPC1TP53 | |
| SCHEMBL3939849 | 0.84 | FAAH (0.98) | FAAHTRPV1KDM2BHRH3EGFR | |
| SCHEMBL2460834 | 0.84 | FAAH (0.54) | FAAHTRPV1LMNAHTTEGFR | |
| SCHEMBL2531475 | 0.83 | FAAH (0.56) | FAAHKDM2BEGFR | |
| SCHEMBL4872597 | 0.83 | FAAH (0.72) | FAAHNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | claimed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | claimed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | claimed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | claimed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | PARK7, PTGIS, PTGES | FAAH 207/4885TRPV1 224/4885KDM2B 3785/4885 |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | TRPV1, TRPV3, TRPA1 | FAAH 334/4885TRPV1 1/4885KDM2B 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.